Nov 15, 2026
NeuroTrax Science Team and Glen M. Doniger, PhD
Video Summary: https://youtu.be/vjAiPc1x8c4
NeuroTrax is a digital neuromarker developed by clinicians and neuroscientists, with initial validation in 2003 (1) and more than 250 peer-reviewed publications.
Amyloid plaques are a “hallmark sign of Alzheimer’s disease” according to the FDA (2). Identifying amyloid helps clinicians investigate symptoms, and amyloid pathology must be confirmed before initiating LEQEMBI (lecanemab) or KISUNLA (donanemab) (3,4).
Assessment previously relied on PET imaging or cerebrospinal fluid testing. FDA-cleared blood tests now provide a less invasive option: Lumipulse for specialized care, Elecsys pTau181 to help rule out amyloid pathology in primary care, and Elecsys pTau217 for rule-in and rule-out assessment across primary and specialty care (2,5,6).
But amyloid shows biology, not cognitive function. Two patients may have positive findings, one with normal cognition and the other with mild cognitive impairment (MCI). A JAMA meta-analysis found that estimated amyloid prevalence among cognitively normal participants rose from 10% at age 50 to 44% at age 90 (7).
The FDA says results “must be interpreted in conjunction with other patient clinical information” (2). The Alzheimer’s Association’s blood biomarker guidance, written for specialized memory care, emphasizes comprehensive clinical evaluation. Its separate primary care guideline recommends validated tools to assess cognition (8,9).
Pairing the biomarker with a digital neuromarker adds objective cognitive performance data across domains over time, adjusted for the patient’s demographic. This matters because LEQEMBI and KISUNLA treatment initiation is indicated at the MCI or mild dementia stage (3,4). Early assessment documents cognitive status during this window; MCI criteria require objective cognitive impairment alongside consideration of everyday independence (10).
Yet a Medicare-based study estimated that approximately 92% of expected MCI cases were undetected in primary care (11). Brief screens may miss impairment: the donanemab expert workgroup notes that patients can meet MCI criteria while achieving a perfect MMSE score (12).
NeuroTrax provides that essential digital cognitive measure. It assesses seven domains, including memory, executive function, attention and processing speed, with millisecond response timing and age- and education-adjusted scores. Alternate forms support retesting with minimal practice effects.
NeuroTrax was selected as a cognitive measure in a three-year, placebo-controlled MCI drug trial published in Neurology, and was reviewed among MCI measures in Alzheimer’s & Dementia (13,14). At least ten registered clinical trials have used NeuroTrax in MCI, Alzheimer’s disease, or other dementias, including Parkinson’s disease dementia (ClinicalTrials.gov).
Usability research in nearly 3,000 clinical patients found that 83% rated the tests easy to use, including 70% of patients older than 75 (15). Staff can administer testing while clinicians see other patients, with reports available immediately afterward.
The biomarker reveals the biology. NeuroTrax measures how the patient is thinking. Together, they provide complementary information for optimal clinical evaluation.
References:
[1] Dwolatzky, T., Whitehead, V., Doniger, G.M., Simon, E.S., Schweiger, A., Jaffe, D., and Chertkow, H. (2003). Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatrics, 3, 4. DOI: 10.1186/1471-2318-3-4
[2] U.S. Food and Drug Administration. (2025, May 16). FDA clears first blood test used in diagnosing Alzheimer’s disease. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease
[3] Eisai Inc. (2026). LEQEMBI (lecanemab-irmb) prescribing information. Sections 1 and 2.1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975
[4] Eli Lilly and Company. (2025). KISUNLA (donanemab-azbt) prescribing information. Sections 1 and 2.1. https://pi.lilly.com/us/kisunla-uspi.pdf
[5] Roche Diagnostics. (2025, October 13). Roche’s Elecsys pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology. https://diagnostics.roche.com/us/en/news-listing/2025/fda-cleared-ptau181-alzheimers-blood-test.html
[6] Roche. (2026, August 24). Roche receives FDA clearance for Elecsys pTau217, advancing Alzheimer’s disease assessment across primary and specialty care. https://www.roche.com/investors/updates/inv-update-2026-08-24
[7] Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R.J., Visser, P.J., et al. (2015). Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA, 313(19), 1924–1938. DOI: 10.1001/jama.2015.4668
[8] Alzheimer’s Association. (2025). Alzheimer’s Association releases its first clinical practice guideline for blood-based biomarker tests. Alzheimer’s & Dementia, 21(9), e70701. DOI: 10.1002/alz.70701
[9] Atri, A., Dickerson, B.C., Clevenger, C., et al. (2025). Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimer’s & Dementia, 21(6), e14333. DOI: 10.1002/alz.14333
[10] Albert, M.S., DeKosky, S.T., Dickson, D., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270–279. DOI: 10.1016/j.jalz.2011.03.008
[11] Liu, Y., Jun, H., Becker, A., Wallick, C., and Mattke, S. (2024). Detection rates of mild cognitive impairment in primary care for the United States Medicare population. The Journal of Prevention of Alzheimer’s Disease, 11(1), 7–12. DOI: 10.14283/jpad.2023.131
[12] Rabinovici, G.D., Selkoe, D.J., Schindler, S.E., Aisen, P., Apostolova, L.G., Atri, A., Greenberg, S.M., Hendrix, S.B., Petersen, R.C., Weiner, M., Salloway, S., and Cummings, J. (2025). Donanemab: Appropriate use recommendations. The Journal of Prevention of Alzheimer’s Disease, 12(5), 100150. DOI: 10.1016/j.tjpad.2025.100150
[13] Schneider, L.S., Geffen, Y., Rabinowitz, J., Thomas, R.G., Schmidt, R., Ropele, S., Weinstock, M., and the Ladostigil Study Group. (2019). Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology, 93(15), e1474–e1484. DOI: 10.1212/WNL.0000000000008239
[14] Snyder, P.J., Jackson, C.E., Petersen, R.C., Khachaturian, A.S., Kaye, J., Albert, M.S., and Weintraub, S. (2011). Assessment of cognition in mild cognitive impairment: A comparative study. Alzheimer’s & Dementia, 7(3), 338–355. DOI: 10.1016/j.jalz.2011.03.009
[15] Fillit, H.M., Simon, E.S., Doniger, G.M., and Cummings, J.L. (2008). Practicality of a computerized system for cognitive assessment in the elderly. Alzheimer’s & Dementia, 4(1), 14–21. DOI: 10.1016/j.jalz.2007.09.008